Refine by
Diagnosis For Cancer Articles & Analysis
278 news found
The International Agency for Research on Cancer reports that as recently as 2020, there were over 13,000 new cases of cancer in Puerto Rico. Tragically, there were also more than 5,500 deaths due to cancer in Puerto Rico that year alone. The American Association for Cancer Research has reported that more than 40% of all diagnosed cancers in the U.S. can be attributed to preventable causes. ...
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced its extensive portfolio of P53 and TP53 antibodies and solutions to support researchers in the critical field of cancer research. This comprehensive collection of research tools will empower scientists to advance their understanding of P53 and TP53 and their role in cancer development ...
Around half of all men say lack of sexual function is a significant problem to them after prostate cancer intervention, highlighted in an international survey from 32 countries and over 5000 men by the Europa-Uomo group1. Real world evidence is important to understand what is happening to patients in healthcare2, so AngioDynamics welcomed the news last week that the UK’s National Institute ...
Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET CT at baseline Fifth major clinical trial for androgen receptor inhibitor (ARi) darolutamide, covering prostate cancer from early to metastatic stage Bayer further expands ...
ByBayer AG
Nubeqa now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) in ...
ByBayer AG
“This approval is supported by robust data from the ARASENS clinical trial, which demonstrate the benefits of darolutamide plus ADT in combination with docetaxel in extending survival, delaying disease progression and maintaining quality of life for patients with metastatic hormone-sensitive prostate cancer.” Prostate cancer is the most commonly ...
ByBayer AG
Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer New approval based on data from the pivotal Phase III ARASENS trial The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the ...
ByBayer AG
Ali Tinazli's post at the Forbes magazine about "How Technology, Early Diagnoses Can Help Turn The Tide On Prostate Cancer Prognosis" There has never been more hope or promise in the global effort to eradicate cancer. ...
In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.80F[i] At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. ...
ByBayer AG
While cancer mortality has gradually declined over the past several decades in Puerto Rico, there are still more than 10,000 new cases of cancer and over 5,000 deaths each year on the islands. Nationwide, the National Cancer Institute estimates there were over 1,918,000 new cases of cancer diagnosed in 2022 and more than 609,000 people died from cancer that year alone. There are over 100 types ...
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat ...
Prostate cancer is the most commonly diagnosed cancer in men in almost all northern and western European countries.1 Only 30% of men with mHSPC will survive five years or more after diagnosis.2 Most men with mHSPC eventually progress to metastatic castration-resistant prostate cancer (mCRPC), a condition with limited long-term ...
ByBayer AG
In 2019, 4D Path successfully closed a ~USD 4.4M funding round with the Seed Three Convertible Preferred Stock offering, bringing their total funds raised to $6.4M. The latest round will support legal and consulting costs as well as continued expansion of its research, team, infrastructure, data acquisition and business development. 4D Path’s patented precision oncology ...
Vancouver, British Columbia – (January 11, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for ...
Today about 20 cancer treatments approved by FDA and EMA are directed towards specific gene fusions, and the number of drugs available is growing annually. The increased importance of gene fusions in oncology is driving demand from diagnostic laboratories for scalable analytical solutions. RNA can be used to analyze gene fusions. Moreover, while DNA is largely identical in all cells, RNA ...
xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as pancreatic adenocarcinoma. Through this collaboration, xCures will help eligible pancreatic cancer patients access a Phase III clinical study entitled, Targeted Intra-arterial Gemcitabine vs. ...
ByxCures
While DNA is largely identical in all cells, RNA fluctuates considerably both in presence and relative concentrations. The variation reflects the underlying cause of a cell’s character and thus RNA analysis gives a more accurate view of the state cells are in compared to DNA analysis. Gene expression levels are important to analyse, and quantitative RNA sequencing is the most informative ...
BC Platforms (BCP), a global leader in healthcare data management and analytics, today announced that, together with Finland’s Euformatics and Hungary’s Oncompass Medicine, the BCP-led partnership has now successfully been awarded contract for the second phase of developing standardized oncology workflows for a buyer consortium of seven leading central European hospitals*, represented ...
Vancouver, British Columbia – (November 28, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the term of the non-broker warrants (the “Warrants”) issued in relation to ...
Vancouver, British Columbia – (October 27th, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in glioblastoma (GB) ...